<PAGE>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

         [X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                  EXCHANGE ACT OF 1934

                  For the quarterly period ended March 31, 2002

         [ ]      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE
                  ACT

                  For the transition period from ______ to ______


                             LARK TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)

<Table>
<S>                                                                              <C>
                  DELAWARE                                                       73-1461841
         (State or other jurisdiction of                                        (IRS Employer
         Incorporation or organization)                                         Identification No.)
</Table>


                 9441 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 103
                                HOUSTON, TX 77099
                    (Address of principal executive offices)

                                 (713) 779-3663
                           (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No

                APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.   Yes     No
                                                   ----   ----

                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of March 31, 2002, there were 3,521,398 shares of Common Stock, par value
$0.001 per share, outstanding.

Transitional Small Business Disclosure Format (Check one): Yes [ ]   No [X]

================================================================================



<PAGE>



                             LARK TECHNOLOGIES, INC.

                              INDEX TO FORM 10-QSB
                      FOR THE QUARTER ENDED MARCH 31, 2002.


Part I   Financial Information (unaudited)

<Table>
<Caption>
                                                                                              Page
                                                                                              ----
<S>                                                                                           <C>
       Item 1.    Financial Statements

                      Balance Sheet........................................................     1

                      Statements of Operations.............................................     2

                      Statements of Cash Flows.............................................     3

                      Notes to Financial Statements........................................     4

       Item 2.    Management's Discussion and Analysis of
                  Financial Condition and Results of Operations  ..........................     6

Part II  Other Information.................................................................     9

       Item 1.    Legal Proceedings........................................................     9

       Item 2.    Changes in Securities....................................................     9

       Item 3.    Defaults Upon Senior Securities..........................................     9

       Item 4.    Submission of Matters to a Vote of Security Holders   ...................     9

       Item 5.    Other Information........................................................    10

       Item 6.    Exhibits and Reports on Form 8-K.........................................    10

Signatures.................................................................................    11
</Table>



                                        i
<PAGE>
                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS
                             LARK TECHNOLOGIES, INC.
                                  BALANCE SHEET

<Table>
<Caption>
                                                                                   March 31, 2002
                                                                                   --------------
                                                                                     (Unaudited)
<S>                                                                                <C>
ASSETS
Current assets:
               Cash and cash equivalents                                           $     613,821
               Accounts receivable (net)                                                 850,064
               Due from related parties                                                    6,946
               Work-in-process                                                            62,759
               Prepaid expenses                                                           91,694
                                                                                   -------------
Total current assets                                                                   1,625,284

Property and equipment, net                                                            1,100,774
Other assets, net                                                                         13,641
                                                                                   -------------
Total assets                                                                       $   2,739,699
                                                                                   =============

LIABILITIES AND STOCKHOLDERS' EQUITY
               Current liabilities:
               Accounts payable                                                    $     233,531
               Due to related parties                                                      5,989
               Notes payable                                                             231,194
               Capital lease obligations-current portion                                 199,024
               Accrued expenses                                                          168,403
               Customer deposits                                                         460,938
                                                                                   -------------
Total current liabilities                                                          $   1,299,079

Note payable-long term portion                                                            28,111
Capital lease obligations-long term portion                                              215,764
Deferred rent expense                                                                     30,195
                                                                                   -------------
Total Liabilities:                                                                     1,573,149

Stockholders' equity
               Preferred stock, $0.001 par value:
                    Authorized shares - 2,000,000
                    None issued and outstanding
               Common stock, $0.001 par value:
                    Authorized shares - 8,000,000
                    Issued shares:3,521,395 and outstanding shares:3,516,895               3,521
               Additional paid-in capital                                              2,670,343
               Treasury Stock at cost                                                     (4,945)
               Accumulated comprehensive loss                                             (5,994)
               Accumulated deficit                                                    (1,496,375)
                                                                                   -------------
Total stockholders' equity                                                             1,166,550
                                                                                   -------------
Total liabilities and stockholders' equity                                             2,739,699
                                                                                   =============
</Table>



See accompanying notes to the financial statements.



                                       1
<PAGE>



                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF OPERATIONS


<Table>
<Caption>
                                                          Three months Ended March 31,
                                                       ----------------------------------
                                                            2001                2002
                                                       ---------------    ---------------
                                                                  (Unaudited)
<S>                                                    <C>                <C>
Revenue:
               Laboratory Services                     $     1,219,875    $     1,480,999

Costs and expenses:
               Costs of services                               967,609            871,129
               Sales, general and administrative               565,362            464,246
                                                       ---------------    ---------------
Total costs and expenses                                     1,532,971          1,335,375
                                                       ---------------    ---------------
Operating income (loss)                                       (313,096)           145,624

Other income and (expense):
               Interest income                                   8,847              1,532
               Interest expense                                (14,264)           (18,930)
                                                       ---------------    ---------------
Total other income (expense)                                    (5,417)           (17,398)
                                                       ---------------    ---------------
Loss before income taxes                                      (318,513)           128,226

Provision for income taxes                                           0             32,000
                                                       ---------------    ---------------
Net loss                                               $      (318,513)   $        96,226
                                                       ===============    ===============



Basic and diluted loss per common share                          (0.09)              0.03
                                                       ===============    ===============
</Table>



See accompanying notes to the financial statements.



                                       2
<PAGE>



                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF CASH FLOWS

<Table>
<Caption>
                                                                   Three Months ended March 31,
                                                                   ----------------------------
                                                                       2001            2002
                                                                    -----------    -----------
                                                                           (Unaudited)
<S>                                                                 <C>            <C>
OPERATING ACTIVITIES
Net income (loss)                                                   $  (318,513)   $    96,226
Adjustments to reconcile net loss
   to net cash provided by (used in) operating activities
               Depreciation and amortization                             87,469        106,852
               Provision for bad debts                                    1,945          4,709
               Changes in operating assets and liabilities:
                    Accounts receivable                                 160,582        246,596
                    Work-in-process                                     (76,308)        22,081
                    Prepaid expenses                                     22,658        (12,612)
                    Due to/from related parties                           7,372         (6,827)
                    Accounts payable                                     41,983       (115,452)
                    Accrued expenses                                     (5,299)        20,697
                    Deferred rent expense                                    --          2,331
                    Deposits                                            (52,838)       104,779
                                                                    -----------    -----------
Net cash provided by (used in) operating activities                    (130,949)       469,380

INVESTING ACTIVITIES
Purchases of property and equipment                                     (10,367)       (61,115)
                                                                    -----------    -----------
Net cash used in investing activities                                   (10,367)       (61,115)

FINANCING ACTIVITIES
Proceeds from issuance of notes payable                                  92,000             --
Principal payments on notes payable                                     (29,620)      (161,624)
Principal payments on capital leases                                    (29,584)       (47,080)
Proceeds from exercised stock options                                       730             --
                                                                    -----------    -----------
Net cash provided by financing activities                                33,526       (208,704)
Effect of currancy translation on cash                                       --             18
                                                                    -----------    -----------
Net increase (decrease) in cash and cash equivalents                   (107,790)       199,579
Cash and cash equivalents at beginning of period                        993,324        414,242
                                                                    -----------    -----------
Cash and cash equivalents at end of period                          $   885,534    $   613,821
                                                                    ===========    ===========
</Table>


See accompanying notes to the financial statements.



                                       3
<PAGE>



                             LARK TECHNOLOGIES, INC.
                          NOTES TO FINANCIAL STATEMENTS
                                   (UNAUDITED)


1.       ORGANIZATION

         Lark Technologies, Inc., a Delaware corporation (the "Company" or
"Lark"), was formed on November 16, 1994, as a wholly-owned subsidiary of
SuperCorp Inc. ("SuperCorp"), for the purpose of merging with Lark Sequencing
Technologies, Inc., a Delaware corporation ("Sequencing"), as outlined in a
merger agreement ("Merger Agreement") entered into by SuperCorp and Sequencing
on October 28, 1994. SuperCorp approved the Merger Agreement on September 5,
1995 and by the stockholders of Sequencing on September 12, 1995. Because of the
merger, all of the shares of common and preferred stock of Sequencing were
exchanged for 1,800,000 shares of Common Stock of the Company with a par value
of $0.001 per share, and the 200,000 shares of Common Stock of the Company held
by SuperCorp were distributed to the shareholders of SuperCorp. The Company has
succeeded to all of the business previously undertaken by Sequencing. Lark
provides specialized laboratory services for DNA sequencing to biotechnology
researchers.

2.       ACCOUNTING POLICIES

Basis of Presentation

         The accompanying unaudited interim financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information in footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to these rules and
regulations. The accompanying unaudited interim financial statements reflect all
adjustments which the Company considers necessary for a fair presentation of the
results of operations for the interim periods covered and for the financial
condition of the Company at the date of the interim balance sheet. All such
adjustments are of a recurring nature. Results for the interim periods are not
necessarily indicative of results for the year.

         For financial reporting purposes, the merger of the Company and
Sequencing has been accounted for as a recapitalization of Sequencing, and the
historical financial statements of Sequencing prior to the merger became the
financial statements of the Company.

3.       INVENTORY

         Work in process inventory includes the direct and indirect costs
associated with projects that were started but not yet completed at March 31,
2002. Direct costs include such items as the cost of labor, reagents and
supplies directly associated with each project. Indirect costs include such
items as general supplies, laboratory management, depreciation, and costs to
operate the lab. These costs are applied to each project on the basis of direct
labor hours incurred for the project, up to the point of measurement, such as
the end of an accounting period. At March 31, 2002, work in process inventory
was $62,759.

4.       NOTES PAYABLE

         On February 28, 2002, the Company renewed its revolving line of credit
and extended the maturity to December 31, 2002. Under the terms of its revolving
line, the Company may borrow up to $600,000 at the bank's prime rate plus 1.5%
(6.25% at March 31, 2002). The borrowing base of this line of credit is equal to
80% of certain accounts receivable that are no more than 90 days old. On March
31, 2002 the Company had $190,000 outstanding under this line. Under the terms
of the revolving line of credit agreement, the Company is required to maintain
certain financial ratios and a specific level of net worth. As of March 31,
2002, the Company was in compliance with these required financial ratios.



                                       4
<PAGE>



         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, 2001 the company
borrowed $92,000 under this facility. On that same day, the advance line feature
of this loan converted to a fixed facility requiring monthly payments over a 36
month period at the bank's prime rate plus 1.5% (6.25% at March 31, 2002). As of
March 31, 2002, a balance of $58,778 remained on this loan.

         Other debt totaled $10,527 at March 31, 2002 and is primarily to
finance commercial insurance policies for less than one year at various rates of
interest.

5.       EARNINGS PER SHARE

                  The following table sets forth the weighted average shares
outstanding for the computation of basic and diluted earnings per share:


<Table>
<Caption>
                                                   For the three months ending
                                                            March 31,
                                                      2001              2002
                                                   ----------        ---------
<S>                                                <C>               <C>
Weighted average common shares outstanding:         3,516,455        3,516,898
Dilutive securities - employee stock options:         115,219          263,731
                                                   ----------        ---------
Weighted average common shares outstanding
 Assuming full dilution:                            3,631,674        3,780,629
                                                   ==========        =========
</Table>


         Options to purchase 455,440 and 420,940 shares of common stock were
outstanding during 2001 and 2002 but were not included in the computation of
diluted earnings per share because the effect would be antidilutive.

5.       COMMITMENTS AND CONTINGENCIES

         The Company is involved in various legal proceedings that have arisen
in the ordinary course of business. In the opinion of management, based on
consultations with counsel and a review of the facts, the ultimate liability to
the Company will not have a material effect on the financial position of the
Company.


Stock Options and Warrants

         During the quarter, 222,000 options were issued to employees and
directors of the Company.

Leases

         The Company leases certain real estate for its corporate office in
Houston, Texas and branch office in the United Kingdom, as well as certain
equipment under non-cancelable lease agreements, which expire at various dates.
In late January 2000, the Company moved into its new corporate headquarters and
lab facility. This new facility provides the Company with approximately 15,000
square feet on one level for a period of 10 years. Total rent expense for all
operating leases for the quarter ended March 31, 2001 and 2002 was $65,760 and
$103,452, respectively.

         Future minimum payments under these operating leases are as follows:

         For the quarter ending March 31,

<Table>
<S>                                                          <C>
                  2002                                       $  211,884
                  2003                                          161,825
                  2004                                          161,825
                  2005                                          169,313
                  2006                                          168,830
                  Thereafter                                    467,307
                                                             ----------
                                                             $1,340,984
</Table>



                                       5
<PAGE>



         The gross amount of assets recorded under capital leases at March 31,
2002 was $654,089. The related accumulated amortization was $157,330 at March
31, 2002. Under the terms of the capital leases, the Company is obligated to
make payments as set forth in the table below and, subject to certain
conditions, may purchase the equipment at the end of the lease for a nominal
amount.

         Future minimum payments under these capital leases are as follows:

<Table>
<S>                                                           <C>
                  2002                                        $  177,987
                  2003                                           188,536
                  2004                                            79,835
                  2005                                            20,150
                  2006                                             8,396
                                                              ----------
                                                              $  474,904

         Less interest portion of payments                        60,116

         Net present value of lease payments                     414,788

         Less current portion                                    199,024
                                                              ----------

         Capital lease obligation less current portion        $  215,764
                                                              ==========
</Table>


         Amortization of capital lease assets is included in depreciation
expense.

Patent License Agreement

         Effective June 15, 1995, the Company entered into an exclusive patent
sub-license agreement with another biotech company. The agreement grants to the
Company an exclusive license to certain "Licensed Patent Rights" of this third
party and requires the Company to perform research and development efforts as
defined in the agreement. The Company is required to pay the third party a
royalty of 25% to 50% of all consideration the Company receives as a result of
sales of licensed products and licensed processes or a sub-license or assignment
of the Company's rights under the agreement. If the Company does not meet the
research and development milestones as defined in the agreement, or is unable to
successfully commercialize the results of the research and development efforts,
the agreement will terminate. Otherwise, the agreement will terminate upon the
dissolution of the Company or the expiration of the "Licensed Patent Rights".
The Company may also terminate the agreement with 60 days written notice to the
third party.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

         The following discussion and analysis should be read in conjunction
with the Financial Statements and the accompanying Notes herein, and is
qualified entirely by the foregoing and by other more detailed financial
information appearing elsewhere.

BUSINESS OF LARK

Lark is a leader in providing contract molecular biology services to the
pharmaceutical, biotechnology and agbio industries. Lark's services are used
worldwide by research organizations and drug development institutions to
accelerate their efforts in bringing products to the market. Lark's contract
research service portfolio consists of over a hundred different molecular
biology services in the areas of Nucleic Acid Extraction Services, DNA
Sequencing Services, Genetic Stability Testing Services, Gene Expression and
Detection Services, and Custom Molecular Biology Services. A highly trained and
educated scientific staff working in a facility that is compliant with the Food
and Drug Administration's ("FDA") Good Laboratory Practices ("GLP") (CFR Title
21, Part 58) performs all of these services.

CUSTOM DNA SEQUENCING SERVICES

The foundation of the company is based upon a broad breadth of DNA sequencing
services. Approximately 75% of projects currently booked by the Company are for
Custom DNA Sequencing Services. The Company has extensive expertise in DNA
sequencing and has incorporated multiple sequencing technologies into its
laboratory to



                                       6
<PAGE>



accommodate both high throughput and highly complex projects. Depending upon the
nature of a project, Lark will develop an optimal sequencing strategy to
generate consistent, high quality sequence data for use in applications spanning
basic research to FDA submissions.

GENETIC STABILITY TESTING ("GST") SERVICES

Lark introduced genetic stability testing as a product offering in 1996 to
assist clients in meeting the regulatory guidelines established for development
and maintenance of specific genetically engineered biotechnology products. Lark
analyzes and provides a comprehensive report on the genetic integrity of cell
banks used to produce recombinant proteins, monoclonal antibodies, gene therapy,
and vaccine products, which is essential to creating a reliable process,
producing a pure biologic product in high yield. The Company believes the need
for these services is growing rapidly with the number of biotechnology products
entering the clinical development pipeline. The FDA is requiring this work be
performed according to GLP guidelines, a key differentiating feature of Lark's
services. True GLP guidelines are not commonly followed in research laboratories
and many service laboratories due to the rigorous demands of documentation and
adhesion to the quality assurance regulations. Lark's entire laboratory operates
according to GLPs but it is particularly important for performing the genetic
stability testing services.

GENETICALLY MODIFIED ORGANISM ("GMO") TESTING SERVICES

Lark provides services for identification and characterization of genetically
modified ("GM") crops and plants. Several effective services have been developed
for genetic testing of food and agricultural products. These laboratory services
offer a broad range of genetics-based assays for qualitative and quantitative
analysis of biotech modifications in plants such as corn, soy and other grain
products. Companies are requiring GMO testing of ingredients for labeling
requirements and to ensure the presence or absence of genetically enhanced
characteristics. This area clearly has the potential for tremendous growth as a
result of the increasing pressures to label and certify all agricultural
products.

GENE EXPRESSION AND DETECTION SERVICES

The genomics initiative continues to provide an abundance of gene sequence
information albeit little information regarding the function of genes in their
biochemical pathways. Lark continues to identify services it can offer to assist
clients in ascertaining the biological role of a gene by determining if, when,
and at what level a gene is being expressed in any number of samples of
interest. These services can be important in identifying novel genes, confirming
the validity of a gene as a drug target, and monitoring a target gene through
the product development process. These services are highly complementary to
genomic research and will continue to be of growing importance to companies
applying genomics to their product development efforts. Lark will continue to
expand the number of services it offers for gene expression and detection
purposes by actively seeking technologies, which meet the growing needs of its
client base.

CUSTOM CORE MOLECULAR BIOLOGY SERVICES

Many of the custom projects Lark performs require the application of molecular
biology techniques either upstream or downstream from the main service provided.
As a result, Lark has developed the ability to perform a breadth of molecular
biology techniques, which can be offered as a complement to another service, or
as a stand-alone service. The Company envisions an expanding list of custom
services as new technologies and advances occur in the field of molecular
biology.

         In 1995 Lark undertook a senescence gene discovery program for its own
account. Although several genes were discovered in this program, lack of gene
functionality coupled with license issues caused Lark to reduce its funding for
this program. Lark continues to work towards license issue resolution and
eventual potential sublicense agreements.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company's discussion and analysis of its financial condition and results of
operations are based upon its financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States.
The preparation of these financial statements requires the Company to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and
liabilities. On an on-going basis, the Company evaluates these estimates,
including those related to customer bad debts, estimated useful lives of
property and equipment, and income taxes. The Company bases its estimates on
historical experience and on various other assumptions that are believed to be
reasonable under the



                                       7
<PAGE>



circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates.

The Company believes the following critical accounting policies reflect the more
significant judgments and estimates used in the preparation of the financial
statements:

ALLOWANCE FOR DOUBTFUL ACCOUNTS--The Company maintains an allowance for doubtful
accounts for estimated losses resulting from the inability of our customers to
pay for laboratory service fees. The Company generally requires a deposit of
approximately 50% of the total anticipated billings prior to commencing work on
larger laboratory service projects. Historically, the Company has not
experienced significant bad debts. However, if the financial condition of the
Company's customers were to deteriorate rapidly, resulting in nonpayment, the
Company could be required to provide additional allowances for doubtful accounts
which would decrease net income in the period that this determination was made.

PROPERTY AND EQUIPMENT--Property and equipment relate primarily to laboratory
equipment and computer equipment. These costs are depreciated or amortized over
the estimated useful lives of the assets. If technology related to the
laboratory equipment or computer equipment was to rapidly change, the estimated
useful lives of existing equipment may be shortened. This would result in
accelerating depreciation and amortization expense, which would decrease net
income in the periods following such a determination. Additionally, effective
January 1, 2002, the Company periodically evaluates the costs of property and
equipment for impairment in accordance with Statement of Accounting Standards
No. 144, "Accounting for Impairment or Disposal of Long-Lived Assets." If events
or circumstances were to indicate that any of the long-lived assets might be
impaired, the Company would be required to analyze the estimated undiscounted
future cash flows from the applicable assets. If the carrying value of the asset
were less than the undiscounted cash flows, the Company would be required to
record an impairment loss, which would reduce net income, to the extent that the
carrying value of the asset exceeded fair value.

DEFERRED TAXES--The Company has recorded a valuation allowance to reduce net
deferred tax assets to zero as a result of the Company's cumulative loss
position and the uncertainty of the Company's ability to realize the net
deferred tax assets in the future. If the Company were able to realize the
deferred tax assets in the future, an adjustment to reduce the valuation
allowance would increase net income.

RESULTS OF OPERATIONS

         GROSS REVENUES. Gross revenues increased 21% from $1,219,875 to
$1,480,999 for the three-month periods ended March 31, 2001 and 2002,
respectively. The increase in revenues for the quarter was the result of
increased sales in most services with the largest growth occurring in our
quantitative PCR services

         COSTS OF SERVICES. Costs of services consist primarily of labor and
laboratory supplies. Costs of services decreased 10% from $967,609 to $871,129
for the three-month periods ended March 31, 2001 and 2002, respectively. The
decrease for the quarter was a result of our continued focus on cost containment
and increasing efficiencies. Costs of services as a percentage of revenue were
79% and 59% for the three-month periods ending March 31, 2001 and 2002
respectively.

         SALES, GENERAL AND ADMINISTRATIVE EXPENSES. Sales, general and
administrative expenses consist primarily of salaries and related costs,
depreciation, amortization, legal and professional costs, rent, travel, and
advertising. Sales, general and administrative expenses decreased 18% from
$565,362 to $464,246 for the three-month periods ended March 31, 2001 and 2002,
respectively. The decrease resulted mainly from a reduction in payroll. Sales,
general and administrative expenses as a percentage of revenue were 46% and 31%
for the three-month periods ended March 31, 2001 and 2002, respectively.

         VARIABILITY OF FUTURE OPERATING RESULTS The growth in quarterly
revenues was largely attributable to increased sales in various product lines.
Although the Company expects higher and less variable revenue streams resulting
from the implementation of our business strategies, the ultimate success of
these changes cannot be reasonably predicted.

         LIQUIDITY AND CAPITAL RESOURCES. Operating cash flow was ($130,949) and
$469,380 for the three-month periods ended March 31, 2001 and 2002,
respectively. The positive operating cash flow for the period ending March 31,
2002 occurred mainly as a result of increased accounts receivable of $246,596
and increased customer deposits of $104,779.



                                       8
<PAGE>



         On February 28, 2002, the Company renewed its revolving loan facility
through December 31, 2002, and may continue to borrow up to $600,000 under the
terms of the credit line. As of March 31, 2002, $190,000 was outstanding on this
line and the Company was in compliance with all of the required financial ratios
for this facility.

         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, 2001, the company
borrowed $92,000 under this facility. On that same day, the advance line feature
of this loan converted to a fixed facility requiring monthly payments over a 36
month period at the bank's prime rate plus 1.5%.

         CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENT--The following table
summarizes the Company's contractual obligations and commercial commitments as
of March 31, 2002 and the effect they are expected to have on its liquidity and
capital resources:

<Table>
<Caption>
Contractual                                                  Less than                         After
Obligations                                   Total           1 Year         1-3 Years        3 Years
----------------------------------------   -------------   -------------   -------------   -------------
<S>                                        <C>             <C>             <C>             <C>
Revolving line of credit                   $     190,000   $     190,000   $          --   $          --
Other credit facilities                           69,305          41,194          28,111              --
Capital lease obligations                        414,788         199,024         187,218          28,546
Non-cancelable operating leases                1,340,984         211,884         492,963         636,137
                                           -------------   -------------   -------------   -------------
Total contractual obligations              $   2,015,077   $     642,102   $     708,292   $     664,683
                                           =============   =============   =============   =============
Other commercial commitments:
Revolving line of credit availability      $     273,627   $     273,627   $          --   $          --
                                           =============   =============   =============   =============
</Table>


         MATERIAL COMMITMENTS. The Company currently has no outstanding material
commitments.


                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

         On June 29, 2000 Joel S. Kanter sued the Company in U.S. District Court
for the Southern District of Texas, Houston Division. The Company entered into a
letter of intent with the "Kanter Group" in 1999 providing for Mr. Kanter to
conduct, or invest in, a proposed $1,320,000 private offering of Company stock.
The transaction was not completed by the time specified in the letter of intent
(on or before November 1, 1999) and Mr. Kanter and the Company continued to work
on the offering for a time thereafter. Mr. Kanter alleges the Company did not
allow him to complete the offering and seeks damages for the breach of the
letter of intent and for reliance damages for his expenses following expiration
of the letter of intent. The Company's position is that there was no binding
agreement, that the letter of intent, by its own terms, prevents Kanter from
recovering and that Kanter imposed material conditions to the completion of the
transaction which were not set forth in the letter of intent. The litigation has
finished its initial stages of discovery and the Company has filed a motion for
summary judgment. The Company intends to vigorously defend the lawsuit and
Management believes that it is without merit.

ITEM 2.  CHANGES IN SECURITIES

         Not applicable.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

         Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         Not applicable



                                       9
<PAGE>



ITEM 5.  OTHER INFORMATION

         Not applicable.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         No reports on Form 8-K were filed during the quarter ending March 31,
2002.

Index of Exhibits

         2.1(1)   The Agreement of Merger of November 18, 1994, between Lark
                  Technologies, Inc. and Lark Sequencing Technologies, Inc.
                  providing for the merger of Lark Sequencing Technologies, Inc.
                  into the Company.

         3.1(1)   Bylaws of Lark Technologies, Inc., as amended.

         3.2(1)   The Certificate of Incorporation of Lark Technologies, Inc.,
                  as amended.

         4.1(2)   Lark Technologies, Inc. 2000 Stock Option Plan adopted by the
                  Company.


(1) Incorporated by reference from the Company's Registration Statement on Form
S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit numbering
system used in Form S-4 differed from that used in this Form 10-QSB (8a, 2d, 2c,
6b, 6c, 6d-1, and 6f, respectively).

(2) Incorporated by reference from the Company's Registration Statement on Form
S-8 dated September 21, 2000, Commission File No. 333-46280.



                                       10
<PAGE>



                                   SIGNATURES


In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                       Lark Technologies, Inc.
                                             (Registrant)



Date May 13, 2002                      /s/ Carl Balezentis
-----------------                      -----------------------------------------
                                                  Carl Balezentis
                                         President and Chief Executive Officer




                                       11